Jusqu’à
version
papier
version
numérique
Up to 50% off
et de nombreux cadeaux
au choix
The AstraZeneca vaccine will be administered in France from this Friday, March 19, Jean Castex announced last night at a press conference.
In recent weeks, fifteen European countries, including France, had suspended the use of this vaccine as a precautionary principle, following the news of several cases of thrombosis.
“The opinion of the European Medicines Agency (EMA) confirms that the AstraZeneca vaccine is a vaccine that is only very effective in combating the emergence of serious bureaucracy of the disease, but that it is also a safe and innocent vaccine,” he stated. the first Minister. Jean Castex himself will be vaccinated at 2:30 p. m. at the Bégin military hospital, in Saint-Mandé (Val-de-Marne), with a dose of AstraZeneca “to show that we can have full confidence,” he said.
Une enquête menée par le Comité pour l’évaluation des risques en matière de pharmacovigilance (Prac), comité de sécurité de l’EMA, a permis d’établir que le vaccin “n’est pas lié à une augmentation des cas de caillots sanguins”, a expliqué Emer Cooke, directrice exécutive de l’EMA, lors d’une conférence de presse jeudi 18 mars, mais un lien “ne peut être exclu définitivement”, concède-t-elle.
“La sécurité des vaccins est primordiale et nous nous félicitons des décisions des régulateurs qui affirment le bénéfice de notre vaccin pour arrêter la pandémie”, a salué Ann Taylor, médecin chef du groupe AstraZeneca.
The European Medicines Agency is under pressure that the vaccine’s “benefits in combating the still-prevalent threat of COVID-19 (which in turn causes bleeding disorders and can be deadly) continue to outweigh the threat of side effects” and that “the vaccine is not related to an accumulation of the overall risk of blood clots (thromboembolic events) in those who suffer from it. “
It adds that “there is no evidence of similar exposure to express batches of the vaccine or specific production sites,” but acknowledges that the vaccine “may be relevant in very rare cases of blood clots related to thrombocytopenia, i. e. , low levels of platelets in the blood. “(elements of blood clots) with or without shock, adding rare cases of blood clots in the vessels that drain blood from the brain (CVST). “
In a new opinion, the High Health Authority (HAS) considers that vaccination can be resumed, but recommends “at this time” to use it “only for people aged 55 and over” and to give preference to mRNA vaccines (Pfizer-BioNtech, Moderna) in people under 55 years of age.
“Il y a un doute de surrisque dans la catégorie des moins de 55 ans. Cela nous conduit de recommander le vaccin aux 55 ans et plus”, a déclaré Dominique Le Guludec, présidente de la HAS, lors d’une conférence de presse.
For the rest of those under 55 years of age who have already received a first dose, the HAS indicates that “very soon it will take a position on the modalities of management of the second dose”.
According to a study conducted by the head of the hematology service at the University Hospital in Oslo, Norway, the AstraZeneca vaccine is solely to blame for these serious side effects. “There is no other cause than the vaccine for this strong immune reaction. “Professor Pal Andre Holme was quoted by the newspaper Verdens Gang: “We inject the vaccine to get an immune reaction opposite to what we want to be protected from. The progression of the antibodies is then obtained, among other things. Some antibodies can then react to activate platelets, as in those cases, and cause a blood clot, he said.
For the moment, Norway and Sweden have announced that they will not resume vaccination with AstraZeneca, despite the EMA’s conclusions.